Aldesleukin

DB00041

biotech approved

Deskripsi

Aldesleukin, a lymphokine, is produced by recombinant DNA technology using a genetically engineered E. coli strain containing an analog of the human interleukin-2 gene. Genetic engineering techniques were used to modify the human IL-2 gene, and the resulting expression clone encodes a modified human interleukin-2. This recombinant form differs from native interleukin-2 in the following ways: a) Aldesleukin is not glycosylated because it is derived from E. coli; b) the molecule has no N-terminal alanine; the codon for this amino acid was deleted during the genetic engineering procedure; c) the molecule has serine substituted for cysteine at amino acid position 125.

Struktur Molekul 2D

Struktur tidak tersedia

Peta Jejaring Molekuler
Legenda: Obat • Target • Gen • Enzim • (Panah → menunjukkan arah efek / relasi) • Transporter • Carrier

Profil Farmakokinetik

Waktu Paruh (Half-Life) 13 min-85 min
Volume Distribusi 0.18 l/kg
Klirens (Clearance) -

Absorpsi

Data absorpsi tidak tersedia.

Metabolisme

Data metabolisme tidak tersedia.

Rute Eliminasi

The pharmacokinetic profile of Proleukin is characterized by high plasma concentrations following a short IV infusion, rapid distribution into the extravascular space and elimination from the body by metabolism in the kidneys with little or no bioactive protein excreted in the urine. Following the initial rapid organ distribution, the primary route of clearance of circulating proleukin is the kidney. Greater than 80% of the amount of Proleukin distributed to plasma, cleared from the circulation and presented to the kidney is metabolized to amino acids in the cells lining the proximal convoluted tubules.

Interaksi Obat

1501 Data
Denosumab The risk or severity of adverse effects can be increased when Denosumab is combined with Aldesleukin.
Etanercept The risk or severity of adverse effects can be increased when Etanercept is combined with Aldesleukin.
Interferon alfa-n1 The risk or severity of adverse effects can be increased when Interferon alfa-n1 is combined with Aldesleukin.
Anakinra The risk or severity of adverse effects can be increased when Anakinra is combined with Aldesleukin.
Interferon gamma-1b The risk or severity of adverse effects can be increased when Interferon gamma-1b is combined with Aldesleukin.
Adalimumab The risk or severity of adverse effects can be increased when Aldesleukin is combined with Adalimumab.
Gemtuzumab ozogamicin The risk or severity of adverse effects can be increased when Aldesleukin is combined with Gemtuzumab ozogamicin.
Pegaspargase The risk or severity of adverse effects can be increased when Aldesleukin is combined with Pegaspargase.
Infliximab The risk or severity of adverse effects can be increased when Aldesleukin is combined with Infliximab.
Interferon beta-1b The risk or severity of adverse effects can be increased when Aldesleukin is combined with Interferon beta-1b.
Rituximab The risk or severity of adverse effects can be increased when Aldesleukin is combined with Rituximab.
Basiliximab The risk or severity of adverse effects can be increased when Aldesleukin is combined with Basiliximab.
Muromonab The risk or severity of adverse effects can be increased when Aldesleukin is combined with Muromonab.
Ibritumomab tiuxetan The risk or severity of adverse effects can be increased when Aldesleukin is combined with Ibritumomab tiuxetan.
Tositumomab The risk or severity of adverse effects can be increased when Aldesleukin is combined with Tositumomab.
Alemtuzumab The risk or severity of adverse effects can be increased when Aldesleukin is combined with Alemtuzumab.
Alefacept The risk or severity of adverse effects can be increased when Aldesleukin is combined with Alefacept.
Efalizumab The risk or severity of adverse effects can be increased when Aldesleukin is combined with Efalizumab.
Antithymocyte immunoglobulin (rabbit) The risk or severity of adverse effects can be increased when Aldesleukin is combined with Antithymocyte immunoglobulin (rabbit).
Daclizumab The risk or severity of adverse effects can be increased when Aldesleukin is combined with Daclizumab.
Phenylalanine The risk or severity of adverse effects can be increased when Aldesleukin is combined with Phenylalanine.
Flunisolide The risk or severity of adverse effects can be increased when Aldesleukin is combined with Flunisolide.
Cladribine Aldesleukin may increase the immunosuppressive activities of Cladribine.
Carmustine The risk or severity of adverse effects can be increased when Aldesleukin is combined with Carmustine.
Amsacrine The risk or severity of adverse effects can be increased when Aldesleukin is combined with Amsacrine.
Bleomycin The risk or severity of adverse effects can be increased when Aldesleukin is combined with Bleomycin.
Chlorambucil The risk or severity of adverse effects can be increased when Aldesleukin is combined with Chlorambucil.
Raltitrexed The risk or severity of adverse effects can be increased when Aldesleukin is combined with Raltitrexed.
Mitomycin The risk or severity of adverse effects can be increased when Aldesleukin is combined with Mitomycin.
Bexarotene The risk or severity of adverse effects can be increased when Aldesleukin is combined with Bexarotene.
Floxuridine The risk or severity of adverse effects can be increased when Aldesleukin is combined with Floxuridine.
Indomethacin The risk or severity of adverse effects can be increased when Aldesleukin is combined with Indomethacin.
Tioguanine The risk or severity of adverse effects can be increased when Aldesleukin is combined with Tioguanine.
Dexrazoxane The risk or severity of adverse effects can be increased when Aldesleukin is combined with Dexrazoxane.
Streptozocin The risk or severity of adverse effects can be increased when Aldesleukin is combined with Streptozocin.
Trifluridine The risk or severity of adverse effects can be increased when Aldesleukin is combined with Trifluridine.
Gemcitabine The risk or severity of adverse effects can be increased when Aldesleukin is combined with Gemcitabine.
Epirubicin The risk or severity of adverse effects can be increased when Aldesleukin is combined with Epirubicin.
Chloramphenicol The risk or severity of adverse effects can be increased when Aldesleukin is combined with Chloramphenicol.
Lenalidomide The risk or severity of adverse effects can be increased when Aldesleukin is combined with Lenalidomide.
Altretamine The risk or severity of adverse effects can be increased when Aldesleukin is combined with Altretamine.
Zidovudine The risk or severity of adverse effects can be increased when Aldesleukin is combined with Zidovudine.
Cisplatin The risk or severity of adverse effects can be increased when Aldesleukin is combined with Cisplatin.
Oxaliplatin The risk or severity of adverse effects can be increased when Aldesleukin is combined with Oxaliplatin.
Fluorouracil The risk or severity of adverse effects can be increased when Aldesleukin is combined with Fluorouracil.
Pentostatin The risk or severity of adverse effects can be increased when Aldesleukin is combined with Pentostatin.
Fluticasone propionate The therapeutic efficacy of Aldesleukin can be decreased when used in combination with Fluticasone propionate.
Fluocinolone acetonide The risk or severity of adverse effects can be increased when Aldesleukin is combined with Fluocinolone acetonide.
Linezolid The risk or severity of adverse effects can be increased when Aldesleukin is combined with Linezolid.
Clofarabine The risk or severity of adverse effects can be increased when Aldesleukin is combined with Clofarabine.
Pemetrexed The risk or severity of adverse effects can be increased when Aldesleukin is combined with Pemetrexed.
Fludrocortisone The risk or severity of adverse effects can be increased when Aldesleukin is combined with Fludrocortisone.
Mycophenolate mofetil The risk or severity of adverse effects can be increased when Aldesleukin is combined with Mycophenolate mofetil.
Sulfasalazine The risk or severity of adverse effects can be increased when Aldesleukin is combined with Sulfasalazine.
Dacarbazine The risk or severity of adverse effects can be increased when Aldesleukin is combined with Dacarbazine.
Temozolomide The risk or severity of adverse effects can be increased when Aldesleukin is combined with Temozolomide.
Penicillamine The risk or severity of adverse effects can be increased when Aldesleukin is combined with Penicillamine.
Prednisolone The risk or severity of adverse effects can be increased when Aldesleukin is combined with Prednisolone.
Mechlorethamine The risk or severity of adverse effects can be increased when Aldesleukin is combined with Mechlorethamine.
Azacitidine The risk or severity of adverse effects can be increased when Aldesleukin is combined with Azacitidine.
Carboplatin The risk or severity of adverse effects can be increased when Aldesleukin is combined with Carboplatin.
Methylprednisolone The risk or severity of adverse effects can be increased when Aldesleukin is combined with Methylprednisolone.
Dactinomycin The risk or severity of adverse effects can be increased when Aldesleukin is combined with Dactinomycin.
Azathioprine The risk or severity of adverse effects can be increased when Aldesleukin is combined with Azathioprine.
Hydroxyurea The risk or severity of adverse effects can be increased when Aldesleukin is combined with Hydroxyurea.
Mycophenolic acid The risk or severity of adverse effects can be increased when Aldesleukin is combined with Mycophenolic acid.
Topotecan The risk or severity of adverse effects can be increased when Aldesleukin is combined with Topotecan.
Mercaptopurine The risk or severity of adverse effects can be increased when Aldesleukin is combined with Mercaptopurine.
Thalidomide The risk or severity of adverse effects can be increased when Aldesleukin is combined with Thalidomide.
Melphalan The risk or severity of adverse effects can be increased when Aldesleukin is combined with Melphalan.
Fludarabine The risk or severity of adverse effects can be increased when Aldesleukin is combined with Fludarabine.
Flucytosine The risk or severity of adverse effects can be increased when Aldesleukin is combined with Flucytosine.
Capecitabine The risk or severity of adverse effects can be increased when Aldesleukin is combined with Capecitabine.
Procarbazine The risk or severity of adverse effects can be increased when Aldesleukin is combined with Procarbazine.
Arsenic trioxide The risk or severity of adverse effects can be increased when Aldesleukin is combined with Arsenic trioxide.
Idarubicin The risk or severity of adverse effects can be increased when Aldesleukin is combined with Idarubicin.
Estramustine The risk or severity of adverse effects can be increased when Aldesleukin is combined with Estramustine.
Mitoxantrone The risk or severity of adverse effects can be increased when Aldesleukin is combined with Mitoxantrone.
Lomustine The risk or severity of adverse effects can be increased when Aldesleukin is combined with Lomustine.
Dexamethasone The risk or severity of adverse effects can be increased when Aldesleukin is combined with Dexamethasone.
Eculizumab The risk or severity of adverse effects can be increased when Aldesleukin is combined with Eculizumab.
Decitabine The risk or severity of adverse effects can be increased when Aldesleukin is combined with Decitabine.
Nelarabine The risk or severity of adverse effects can be increased when Aldesleukin is combined with Nelarabine.
Abatacept The risk or severity of adverse effects can be increased when Aldesleukin is combined with Abatacept.
Corticotropin The risk or severity of adverse effects can be increased when Aldesleukin is combined with Corticotropin.
Stepronin The risk or severity of adverse effects can be increased when Aldesleukin is combined with Stepronin.
Hydroxychloroquine The risk or severity of adverse effects can be increased when Aldesleukin is combined with Hydroxychloroquine.
Castanospermine The risk or severity of adverse effects can be increased when Aldesleukin is combined with Castanospermine.
Vorinostat The risk or severity of adverse effects can be increased when Aldesleukin is combined with Vorinostat.
2-Methoxyethanol The risk or severity of adverse effects can be increased when Aldesleukin is combined with 2-Methoxyethanol.
Brequinar The risk or severity of adverse effects can be increased when Aldesleukin is combined with Brequinar.
Aldosterone The risk or severity of adverse effects can be increased when Aldesleukin is combined with Aldosterone.
Pirfenidone The risk or severity of adverse effects can be increased when Aldesleukin is combined with Pirfenidone.
Afelimomab The risk or severity of adverse effects can be increased when Aldesleukin is combined with Afelimomab.
Interferon alfa The risk or severity of adverse effects can be increased when Aldesleukin is combined with Interferon alfa.
Glatiramer The risk or severity of adverse effects can be increased when Aldesleukin is combined with Glatiramer.
Briakinumab The risk or severity of adverse effects can be increased when Aldesleukin is combined with Briakinumab.
Human interferon omega-1 The risk or severity of adverse effects can be increased when Aldesleukin is combined with Human interferon omega-1.
Apremilast The risk or severity of adverse effects can be increased when Aldesleukin is combined with Apremilast.
Canakinumab The risk or severity of adverse effects can be increased when Aldesleukin is combined with Canakinumab.

Target Protein

Interleukin-2 receptor subunit beta IL2RB
Interleukin-2 receptor subunit alpha IL2RA
Cytokine receptor common subunit gamma IL2RG

Referensi & Sumber

Synthesis reference: Hans-Ake Fabricius, Roland Stahn, "Serum-free and mitogen-free T-cell growth factor and process for making same." U.S. Patent US4464355, issued May, 1971.

Contoh Produk & Brand

Produk: 6 • International brands: 0
Produk
  • Proleukin
    Injection • 1.1 mg/1mL • Intravenous • US • Approved
  • Proleukin
    Injection • 1.1 mg/1mL • Intravenous • US • Approved
  • Proleukin
    Injection, powder, lyophilized, for solution • 1.1 mg/1mL • Intravenous • US • Approved
  • Proleukin
    Injection, powder, lyophilized, for solution • 1.1 mg/1mL • Intravenous • US • Approved
  • Proleukin
    Powder, for solution • 22000000 unit / vial • Intravenous • Canada • Approved
  • Proleukin
    Injection, powder, lyophilized, for solution • 1.1 mg/1mL • Intravenous • US • Approved

Sekuens Gen/Protein (FASTA)

Sekuens dimuat saat dibutuhkan agar halaman tetap ringan.
© 2025 Digital Pharmacy Research - Universitas Esa Unggul